Pfizer, Teva Settle Patent Suit Over Blockbuster Drug Xeljanz

Pfizer had claimed Teva’s proposed generic version of 11-milligram Xeljanz XR infringes one of its patents on the blockbuster arthritis drug.

• No details provided in stipulation of dismissal, filed Tuesday but not yet approved in federal court in Wilmington, Delaware
  • Patent expires in March 2034: FDA Orange Book
• Bench trial in the case had been set for January 2022
• Pfizer in January filed a lawsuit claiming Aurobindo’s proposed copycats of Xeljanz’s 5- and 10-mg tablets infringe two patents; that case, also in Delaware, is pending
  • Pfizer in April settled suits citing same two patents against Zydus ...